Journal article
Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: A population-based study
C Keane, F Vari, M Hertzberg, KAL Cao, MR Green, E Han, JF Seymour, RJ Hicks, D Gill, P Crooks, C Gould, K Jones, LR Griffiths, D Talaulikar, S Jain, J Tobin, MK Gandhi
Lancet Haematology | Published : 2015
Abstract
Background: Risk-stratification of diffuse large B-cell lymphoma (DLBCL) requires identification of patients with disease that is not cured, despite initial treatment with R-CHOP. The prognostic importance of the revised International Prognostic Index (R-IPI) and cell of origin of the malignant B cell are established in DLBCL. We aimed to develop a novel, easily applicable, tissue-based prognostic biomarker based on quantification of the tumour microenvironment that is independent of and additive to the R-IPI and cell of origin. Methods: We performed digital hybridisation on the NanoString platform to assess the relation between immune effector and inhibitory (checkpoint) genes in 252 formal..
View full abstractGrants
Funding Acknowledgements
Funding for this study was received from the Leukaemia Foundation of Queensland; the Kasey-Anne Oklobdzijato Memorial fund; the Australasian Leukaemia and Lymphoma Group (Malcolm Broomhead Bequest); the Australian Cancer Research Foundation; the Cancer Council of Queensland and Health and Medical Research Queensland. Roche provided funds towards clinical running of the ALLGNHL21 trial.